Syntactx Appoints Dr. David Deaton as Chief Medical Officer

February 1, 2017—Syntactx recently announced that David Deaton, MD, has joined the company as Chief Medical Officer.

Kenneth Ouriel, MD, who is President and Chief Executive Officer of Syntactx, commented in the company's press release, “Dr. Deaton is experienced in patient care and innovative technologic solutions to improve the long-term results of interventions. Dr. Deaton has been at the forefront of innovation and has a unique ability to look at a clinical problem, dissect out its critical components, and address them one by one to develop a pragmatic solution. We are extremely pleased to welcome Dr. David Deaton as an important member of the Syntactx leadership team.”

Syntactx stated that Dr. Deaton comes to the company after serving as Chief Medical Officer of Endologix. Additionally, Dr. Deaton devotes 1 week per month to clinical vascular surgery at the Cleveland Clinic, where he cares for patients and instructs residents and fellows in the Clinic’s Heart and Vascular Institute in Cleveland, Ohio.

Dr. Deaton received a BA in Chemistry from Haverford College and an MD from Duke University School of Medicine. He completed his surgical residency and research fellowship at the Hospital of the University of Pennsylvania and his vascular fellowship at the University of California at Los Angeles (UCLA).

He has practiced in a variety of private and academic settings, as Chief, Division of Vascular and Endovascular Surgery at MedStar Georgetown University Hospital in Washington, DC. He was also Director, Clinical Vascular Research and Founder and Medical Director, Vascular Noninvasive Laboratory.

Dr. Deaton has been involved in the development and evolution of endovascular aortic therapy since 1993. He was a leading investigator in the first United States endovascular aortic repair (EVAR) trial and provided US Food and Drug Administration panel testimony for the first approved EVAR device in the United States in 1999.

He served as a primary investigator in the phase 1 clinical trials of four different aortic endograft technologies and performed the first-in-man and first United States cases using the Aptus device (Aptus Endosystems, Inc., acquired by Medtronic in 2015). Dr. Deaton has held academic appointments at UCLA, the University of Pennsylvania, East Carolina University, and the University of Maryland in addition to his tenure at Georgetown. He has held leadership positions in several vascular societies, most recently as Chairman of the Political Action Committee of the Society for Vascular Surgery.

His interest in new translational vascular therapies resulted in numerous roles at established and start-up medical device companies over the last 20 years. He has authored both peer and nonpeer reviewed articles as well as vascular text chapters throughout his career and has been a speaker and faculty member at approximately 150 meetings in the United States and internationally.

Founded by Dr. Ouriel, Syntactx is a Contract Research Organization that delivers clinical research services based on a well-defined strategy, collaboration, and transparency, thereby reducing time to execution and minimizing the overall risk of a project. The company takes clinical trials from product inception through market introduction and postmarket studies. Syntactx’s strategic partners include clinicians, academic and nonacademic institutions, and regulatory agencies.

Syntactx is headquartered in New York, New York, and has offices in Belgium and partners across the United States and in Europe.